). in the absence of ligand, tr is bound to corepressor proteins 6, 7 as a complex on responsive promoters that prevents transcriptional activation. ligand binding to tr causes the dissociation of corepressors and the subsequent association of coactivators 8 that stimulate target gene expression. a coactivator family that interacts strongly with trs, as well as other nhrs, is the p160 protein family of steroid receptor coactivators (srcs) [9] [10] [11] that include src1, src2 (grip1/tiF2), and src3 (aiB1/tram1/rac3/actr). all srcs contain a nuclear receptor interaction domain composed of three repeated consensus lXXll motifs, termed NR boxes, and an activation domain that interacts with other coregulatory proteins. the lXXll motif is necessary and sufficient for interaction with nrs. 12, 13 peptides composed of lXXll motifs from src2 family members bind to tr with affinities comparable to full-length src2 protein.
12,14 nr boxes interact with a hydrophobic groove located in the aF-2 region of tr. 15 We have previously identified a proinhibitor β-aminoketone series (sJ1, Fig. 1A ) from a high-throughput screen, which disrupts tr-src2-2 interaction in the presence of t3. 16 sJ1
can undergo deaminiation to form an enone in situ, followed by a modification of a nucleophilic cysteine in the aF-2 cleft. mechanism-of-action studies suggest that sJ1 modifies cys298, one of four accessible cysteines in the aF-2 region of tr, resulting in disruption of src binding. 17 preliminary evaluation of in vivo toxicology revealed significant dose-related cardiotoxicity, suspected to arise from ion channel inhibition. although subsequent chemical optimization work improved the pharmacological properties of sJ1, including increased potency, reduced cytotoxicity, and elimination of herg potassium channel activity, 18 these analogs still exhibit ion channel binding. therefore, new chemotypes of tr-coactivator inhibitors are desired. the goal of this project is to identify new smallmolecule inhibitors that are tr selective by disrupting the association of src2.
metHodS

Protein expression and purification
htrβ lBd (his6; residues t209-d461) was expressed in Bl21(de3) (invitrogen, carlsbad, ca; 10 × 1-l culture) at 20 °c and 0.5 mm isopropyl-1-thio-β-d-galactopyranoside added at 0.6 abs 600 to induce protein expression. When the abs 600 reached 4, cells were harvested, resuspended in 20 ml of buffer/1 l of culture (20 mm tris, 300 mm nacl, 0.025% tween 20, 0.10 mm phenylmethylsulfonyl fluoride, 10 mg of lysozyme, ph 7.5), incubated for 30 min on ice, and then sonicated for 3 × 3 min on ice. the lysed cells were centrifuged at 100 000 g for 1 h, and the supernatant was loaded onto talon resin (20 ml; clontech, mountain View, ca). protein was eluted with 500 mm imidazole (3 × 5 ml) plus ligand (3,3′,5-triiodo-l-thyronine; sigma, st louis, mo). protein purity (>90%) was assessed by sodium dodecyl sulfate polyacrylamide gel electrophoresis (sds-page) and high-pressure size exclusion chromatography, and protein concentration was measured by the Bradford protein assay. the protein was dialyzed overnight against assay buffer (3 × 4 l, 50 mm sodium phosphate, 150 mm nacl [ph 7.2], 1 mm dithiothreitol [dtt], 1 mm edta, 0.01% nonidet p-40, 10% glycerol).
Peptide synthesis and labeling
src2-2 peptide was synthesized and purified by reversephase high-performance liquid chromatography (hplc) at the hartwell center (st. Jude children's research hospital). texas red or fluorescein-maleimide (molecular probes, eugene, or) fluoroprobes were conjugated to the n-terminal cysteine of the src2-2 peptide as described.
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Cell toxicity assay human follicular thyroid carcinoma Wro cells (kindly provided by dr. m. d. ringel) were maintained in rpmi-1640 culture medium supplemented with 10% heat-inactivated fetal bovine serum (FBs), 50 u/ml penicillin, and 50 µg/ml streptomycin. cells were harvested and suspended at 330 000 cells/ml in assay medium (50% dulbecco's modified eagle's medium FIg. 1 . performance of the quantitative high-throughput screen. (A) the structure of the β-aminoketone control inhibitor, sJ1, is shown. (B) mp values and Z′ factor of control wells are shown for each plate screened. the bifurcated Z′ scores of the first ~500 plates resulted from a software problem in one of the two enVision detectors used in the screen. Following correction, the detector configuration was optimized and the Z′ scores aligned with those of the second detector. (c) concentration-response data (black circles) and curve fits (gray lines) of sJ1 titrations from each plate screened are shown. sJ1 was titrated as 16 twofold titrations in duplicate beginning at 46 µm on each plate.
[dmem], 50% F-12 medium without phenol-red [cellgro #16-405-cV; cellgro, manassas, Va], l-glutamine, 10% heatinactivated and charcoal-treated FBs, 100 µm nonessential amino acid, 50 u/ml penicillin, 50 µg/ml streptomycin). approximately 10 000 cells were dispensed in 30 µl/well into 384-well plates (corning 3917; corning, inc., corning, ny) and incubated 12 h at 37 °c and 5% co 2 . compounds and t3 (100 nm final concentration) were added using a pin tool, and plates were incubated 16 h at 37 °c and 5% co 2 . Following incubation, plates were equilibrated at ambient temperature for 30 min, 20 µl of celltiter-glo (promega, madison, Wi) was added, and luminescence was measured using an enVision (perkinelmer, Waltham, ma) reader. the data were normalized to negative (dmso) and positive (5 µm staurosporine) control wells on each plate. compounds were tested in four independent runs, and those displaying concentration-response curves with 30% activity or greater (class 1-3) in at least three runs were considered cytotoxic.
Quantitative high-throughput screen the screen was performed on an integrated robotic platform 20 using the protocol outlined in table 1. in brief, 5 µl/ 1993) . chemical structures and quantitative high-throughput screening (qhts) data were deposited in pubchem (aid 1469 and 1479). although 296 587 samples were screened, curve fits were performed on titration-response data for 292 732 samples because some assay wells failed quality control and were masked.
Follow-up fluorescence polarization assays
For retest, the screening assay was performed as above using 20 nm src2-2 fluoroprobe labeled with either texas red or fluorescein. samples were plated as 24 twofold dilutions in duplicate beginning at 5 mm, and 23 nl was transferred to the assay plate four times to achieve a top concentration of 92 µm.
For confirmation, 20 µl/well 0.6 µm trβ and 20 nm src2-2 texas red or fluorescein fluoroprobe in protein buffer (20 mm tris hydrochloride [ph 7.4], 100 mm nacl, 10% glycerol, 1 mm edta, 0.01% np-40, 1 mm dtt, 1 µm t3, and 4% dmso) were dispensed into black solid 384-well plates (costar 3710; corning) using a Biomek FX (Beckman coulter, Brea, ca) liquid handling system. compounds were plated at 10 threefold dilutions, and 260 nl was transferred to the assay plate to achieve a top concentration of 130 µm. after incubation for 3 h at ambient temperature, the plates were read using an enVision (perkinelmer) plate reader to detect fluorescence polarization of src2-2 texas red (555 nm excitation and 632 nm emission) or src2-2 fluorescein (480 nm excitation and 535 nm emission). Five confirmation compounds were tested in the 1536-well plate format described above and yielded results similar to the 384-well plate format, indicating little or no difference in assay sensitivity for the two plate formats.
Data analysis and SAR derivation
the titration-response data were processed by normalizing mp and total fluorescence (tF) values to controls as follows: % activity = [(V compound − V pos )/(V pos − V neg )] × 100, where V compound denotes the compound well values, V pos denotes the median value of the dmso-treated control wells containing trβ, and V neg denotes the median values of the dmso-treated control well without trβ (free fluoroprobe). mp window was defined as the difference in mp values of the dmso-treated control wells containing free and bound fluoroprobe. tF was calculated as follows: tF = s + 2p, where s and p are fluorescence readings in the parallel and perpendicular channels, respectively. these normalized activity values were then corrected by applying a pattern correction algorithm to remove plate backgrounds such as dispense patterns and edge effects 21 using dmso-only plates placed at 24-plate intervals in the screen as well as at the beginning and end.
concentration-response curves were fit and classified as described. 22 Four major curve classes (1-4) were created based on the completeness of curve, goodness of fit, and efficacy. the compounds with class 1.1, 1.2, and 2.1 curves are statistically the most reliable, whereas the compounds with class 2.2 and 3 curves are less reliable. class 4 compounds are inactive, showing no concentration response. an in-house auto scaffold detection program was used to cluster 511 actives (curve classes 1.1, 1.2, and 2.1 as well as class 2.2 curves with >40% efficacy), yielding 730 structural series and 128 singletons. each series contained at least three compounds of which at least one was active. series were flagged for the following potential liabilities (see Supplemental table S2 for additional details): concentrationdependent changes in total fluorescence in the fluorescence polarization (Fp) assay or at 547 nm excitation and 618 emission, 27 promiscuous aggregation (selectively active in the detergent-free cruzain assay; pubchem aid 2383), promiscuous redox activity (active in the caspase-1 or caspase-7 assay; pubchem aid 889 and 2389), low potency (>20 µm) or low efficacy (<50%), significantly lower actives compared to mean actives in all series using Fisher's exact test (p < 0.05), and promiscuous activity in other assays (promiscuity score >0.5; Supplemental table S1). this process identified eight series and two singletons with no criteria liabilities.
three-dimensional plots of concentration-response data and associated curve fits were made using originpro software (originlab, northampton, ma). screen and follow-up data were deposited into pubchem (aid 1469, 1479, 1570-73).
reSuLtS
Quantitative high-throughput screen for TRβ-SRC2-2 inhibitors
small molecules that prevent the interaction of trβ with the steroid receptor coregulator 2 (src2) were detected using a qhts of a previously described fluorescence polarization assay with a texas red-labeled src2-2 peptide, corresponding to a 20-amino acid region of the nuclear receptor interaction domain. 16 qhts is a method where each compound is assayed at multiple concentrations to generate a titration-response curve for each tested sample. 22 small-molecule inhibitors were identified by a decrease in fluorescence polarization.
For screening, the tr assay was scaled from a 384-well to 1536-well format by reducing the assay volume by one quarter, from 20 µl to 5 µl per well. assay performance was validated in this format using standard procedures. 20 a collection of 292 732 small-molecule samples was tested in the tr assay. the qhts was conducted on an integrated robotic platform where the compounds were assayed at six concentrations, with more than two million wells tested. the screen performed well; of the 1418 assay plates screened, 1380 (97%) plates passed quality control, giving a mean Z′ score of 0.73 and mean mp window of 128 (Fig. 1B) . the plates that failed quality control did so because of reagent dispense problems arising from mechanical problems. the affected rows or plates were masked to exclude these data. the control titration of the β-aminophenylketone inhibitor, sJ1 (Fig. 1A) , 9 present on each plate performed consistently, showing a mean ic 50 of 8.2 ± 5.2 µm (Fig. 1c) .
Identification of TR inhibitors
concentration-response curves (crcs) were fit for the fluorescence polarization (Fp; mp values) and tF data sets (Fig. 2) . as previously described, the crcs were categorized into four general classes. 22 class 1 are curve fits having both upper and lower asymptotes and >0.9 r 2 . class 2 are incomplete curve fits having only one asymptote and >0.9 r 2 . class 3 are lowconfidence curve fits with <0.9 r 2 or have activity at a single concentration. class 1 and 2 curves are divided further into subclasses to indicate efficacies 80% or greater (classes 1.1 and 2.1) or between 30% and 80% (classes 1.2 and 2.2). class 4 compounds are inactive, having either no curve fit or an efficacy below threshold activity (three sd of the mean activity).
the Fp qhts data revealed 1222 compounds with activity (classes 1-3), of which 312 were activators and 910 were inhibitors ( Fig. 2A, table 2 Fig. 3) .
the tF qhts data were used to counterscreen the Fp inhibitors as changes in tF are useful for identifying artifacts arising from compound interferences such as fluorescence, aggregation, or light scattering. 23 From the entire screen, 466 samples showed concentration-dependent increases in tF, and 3943 samples displayed decreases (table 2, Fig. 2B ). this total of 4409 samples comprised 1.5% of the screening collection. of the 511 Fp actives, 212 (41%) showed concentrationdependent changes in tF (data not shown), suggesting the activity of these Fp inhibitors arose from compound interference rather than inhibition of trβ-src association. more than 80% of these interfering compounds showed increases of tF (data not shown).
the Fp inhibitors showed a wide range of potencies. examination of all 511 Fp actives indicated 17 (4%) samples with ic 50 <1 µm and 72 (14%) samples having ic 50 in the range of 1 to 10 µm (table 3). most of these actives displayed class 1 curves, indicating a saturated response. the majority of samples, 409 (80%), had ic 50 values in the range between 10 and 100 µm. almost 70% of these actives showed class 2 curves, which are incomplete and have only an upper asymptote.
after removing the 212 interfering compounds that showed tF activity, 299 Fp inhibitors remained (table 3) . of the 299 inhibitors, 266 were recovered from the molecular libraries small molecule repository, 33 from internal diversity and bioactive libraries, and none from the natural product extract collections. almost all of these inhibitors showed class 1.2 and 2.2 curves, indicating efficacies below 80%. however, the general distribution of potencies of this subset was similar to the total set of Fp inhibitors, where 8 (3%) samples displayed ic 50 <1 µm, 50 (17%) with ic 50 in the range of 1 to 10 µm ic 50 , and 234 (78%) with ic 50 in the range of 10 to 100 µm. clearly, compound optical properties, as measured by tF activity, resulted in high-efficacy Fp false positives over a broad potency range. this is commonly observed in Fp assays. 25 
Identification of TR inhibitor series
to find structurally related compounds, the 511 validated inhibitors were analyzed using a fragment-based approach to yield 730 scaffolds and 128 singletons. compounds containing a common scaffold formed a series. each active could be part of more than one series depending on which part of the compound was used as a scaffold. thus, the number of series was larger than the number of actives clustered. after the series of interest were defined, structurally related compounds that gave either inconclusive activity or no activity were added to each series, thus providing lists containing three or more compounds of which at least one was active. each series and singleton was flagged for the following potential liabilities with the number of series indicated in parentheses: concentration-dependent changes in tF or solution fluorescence at 547 nm excitation and 618 emission (363), promiscuous aggregation (43), promiscuous redox activity (136), ic 50 value greater than 20 µm or efficacy less than 50% (299), underrepresentation of actives compared to the library average (67), and promiscuous activity in other assays (509). series and singletons flagged for potential artifacts (change of total fluorescence intensity, redox interference, and aggregation) or low potency (>20 µm ic 50 ) were excluded from the follow-up study.
the remaining series were clustered further such that series with similar scaffolds were merged, resulting in 42 series and 23 singletons. From this list, compounds were chosen for retest using the following method: all singletons were chosen and for each series, two actives and one inactive were chosen, when available. this process yielded a set of 103 available compounds containing 92 actives and 11 inactives.
the retest samples were characterized in two tr Fp assays, one using a src2-2 fluoroprobe labeled with texas red and the other using the same probe labeled with fluorescein, as well as a cell viability assay. the samples were tested as concentration-response experiments using a range of 24 twofold dilutions in duplicate beginning at 92 µm. samples that displayed class 1 to 3 curve fits were scored as active. compounds having efficacy below 40% were considered active, but the ic 50 values were not considered reliable and therefore not used for subsequent work. the texas red Fp assay identified as active 75 (83%) of 92 qhts positives as well as 7 of 11 qhts inactives (Supplemental table S2). the orthogonal fluorescein Fp assay was used to confirm activity and eliminate compounds that interacted with the texas redlabeled fluoroprobe. the fluorescein assay identified as active 58 of 92 qhts positives as well as 4 of 11 qhts inactives. a viability assay using Wro cells showed 8 compounds were toxic. merging these results to select the compounds with a high probability of true activity indicated 38 compounds (19 series and 4 singletons) were active with 40% or greater efficacy in both Fp assays, free of compound interference, and not toxic in cells (Supplemental table S2) . to prioritize compounds for subsequent work, the 38 retest actives were examined to eliminate compounds showing undesirable chemical or biological properties, such as low potency in one or both Fp assays. in addition, one series (#38; Supplemental table S2) was excluded because of structural similarity to the β-aminoketone scaffold identified previously as a trβ-coactivator inhibitor. 16 this process identified four structurally distinct series and two singletons for further characterization. independent samples of these actives as well as one analog were tested in the two Fp assays to confirm activity (Supplemental table S2). one series containing a methylsulfonylnitrobenzoate (msnB) core (#1) and one singleton (#s16), the plant alkaloid geneseroline, 26 confirmed as active in both Fp assays (Fig. 4, Supplemental table S2) . two members of the msnB series showed about 5 µm ic 50 in both Fp assays, whereas geneseroline was weakly active with an ic 50 above 30 µm in both assays (Supplemental table S2). the msnB series was judged a validated screening hit, and subsequent studies have shown this series is a specific and irreversible antagonist that inhibits a tr-mediated gene reporter in cells. (A) the structures of active and inactive msnB analogs identified from the qhts are shown. the compounds within the box are inactive 2-(cyclohexanecarboxamido)-2-oxoethyl benzoate compounds structurally related to the msnB series but lack the nitrosulfonylphenyl group. (B) the structure of the geneseroline is shown. compound names in bold indicate independent samples that were tested in confirmation studies. dIScuSSIon in this study, we have performed a qhts to identify compounds that inhibit the interaction between trβ and src2-2. the titration-response screen of more than 290 000 samples enabled us to determine the activity of each compound as well as the potency, efficacy, and other pharmacological measures of the actives. using only the primary qhts data, actives were prioritized, interfering compounds were identified, and nascent structure-activity relationships were derived. this analysis allowed the selection of a small number of compounds for retest and the inclusion of analogs and inactives for series of interest. confirmation studies of select actives with sufficient potency and chemical tractability identified a msnB containing series as a new class of thyroid hormone receptor-coactivator antagonists.
although the goal of this qhts was to recover compounds that decreased Fp via fluoroprobe displacement, the screen recovered 312 compounds that showed Fp increases. the tF data set indicated that 41% of these samples showed concentration-dependent decreases in tF, and an additional 28% showed increases (data not shown). these increases in Fp and changes in tF may reflect compound effects on light scattering 23, 24 or the emission and polarization of the fluoroprobe. in the latter case, compounds may cause the fluoroprobe to aggregate, resulting in both increased fluorescence and anisotropy. a less likely effect is compound autofluorescence because spectroscopic profiling of more than 70 000 library samples shows that fewer than 10 samples fluoresce in the far-red excitation and emission spectra used in this assay. 27 there were a minority of compounds that showed increases in both Fp and tF. of the 312 compounds with increased Fp and 466 compounds with increased tF, only 87 compounds showed increases in both.
our assay used fluorescence polarization to detect the interaction of the trβ lBd with a src2-2 fluoroprobe. however, other assay formats, such as time-resolved fluorescence resonance energy transfer (tr-Fret) and alphascreen, have been used to detect other nhr-coactivator interactions. [28] [29] [30] although all of these methodologies have been implemented to identify validated small-molecule inhibitors, each has advantages and liabilities (reviewed in Woelcke and hassiepen 31 ). in general, Fp formats are simpler, requiring the labeling of only one probe, which can result in lower assay costs and greater ease of implementation. however, Fp assays typically require micromolar concentrations of target protein, resulting in lower sensitivity, and are susceptible to a variety of compound interferences. 23 methods based on tr-Fret determine a ratio of two fluorescent emissions and are less susceptible to compound interferences, although artifacts do occur. 32 antibody-based tr-Fret formats use nanomolar concentrations of target, 28, 29 permitting greater sensitivity in detecting potent inhibitors. however, these formats are more complex where probe reagents may be difficult to label or expensive to generate and may make large-scale screening cost prohibitive. 31 the trβ-src2-2 qhts was very selective in identifying actives. only 299 Fp inhibitors (0.1% of screening collection) were recovered from the qhts that were free of compound interference, as judged by total fluorescence activity. this percentage is similar to an earlier screen using this assay where 0.02% actives were identified by assaying compounds at a single concentration of 30 µm. 16 our fivefold higher recovery of actives reported here is due likely to the titration-based screening method used 22 combined with a higher starting concentration of 92 µm for most of the screened compounds. the low yield of trβ-src2-2 inhibitors may be attributed to several factors: the difficulty in disrupting protein-protein interactions with small molecules, 33 the relatively high concentration of target protein (0.6 µm), and the shallow pocket of trβ that interacts with src2. 17 indeed, many of the compounds that retested as positive in both Fp assays had ic 50 values greater than 20 µm (Supplemental table S2), indicating that most compounds weakly disrupted the interaction between trβ and src2-2.
however, the qhts identified one novel series that inhibited trβ and src2-2 association with an ic 50 value of 5 µm. this msnB series represents a new chemotype inhibitor of this interaction. eight msnB analogs were tested in the qhts, of which three were active. Because the qhts assayed each compound at six concentrations, the determined potencies and efficacies allowed us to derive a nascent structure-activity relationship for this series. all msnB compounds containing either a hydrophobic imide (mls000517530-01) or amide (mls000389544-01 and mls001003365-01) were active, whereas those containing an aniline (mls000517219-01 and mls001017631-01), β-aminosulfone (mls000336487-01), or oxadiazole (mls001010708-01 and mls001003284-01) were inactive (Fig. 4A) . these results suggest that a hydrophobic group is needed at this position for activity. replacement of the msnB group in mls000517530-01 with other aromatic groups (mls000517502-01, mls000776485-01, and mls000565662-01) also resulted in loss of the activity, implying that this group is essential. Further studies using a broader range of analogs will be needed to confirm these hypotheses.
the msnB series is structurally distinct from the previously described β-aminoketones 16 and therefore represents a novel tr-src2 inhibitor scaffold. the β-aminoketone series of inhibitors has been successfully modified to improve potency, reduce cytotoxicity, and improve physiochemical determinants of bioavailability. 18, 34 however, this class has an inherent cardiotoxicity due to the interaction of the requisite aminoketone moiety with cardiac ion channels. although optimization has lessened the impact of this issue, the liability has not been eliminated. the new msnB series does not possess chemical moieties expected to cause this liability and thus presents advantages over the earlier series. structural studies indicate that β-aminoketones series members alkylate cysteine 298 in the aF-2 pocket of trβ, which normally forms the interface for binding coactivators. 17 initial characterization of the msnB series indicates it binds irreversibly to trβ lBd and may inhibit in a similar manner. 35 Future studies will elucidate the mechanism of msnB inhibition more fully.
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